- Home
- SDHY vs PROK Comparison
SDHY vs PROK Comparison
Compare SDHY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHY | PROK |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.2M | 417.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDHY | PROK |
|---|---|---|
| Price | $16.36 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 94.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.93 | $0.46 |
| 52 Week High | $15.50 | $7.13 |
Technical Indicators
Market Signals| Indicator | SDHY | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 49.07 |
| Support Level | $16.18 | $2.06 |
| Resistance Level | $16.58 | $2.59 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 42.84 | 47.46 |
Price Performance
Historical ComparisonAbout SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.